{
    "clinical_study": {
        "@rank": "62251", 
        "acronym": "ORHEO", 
        "arm_group": {
            "arm_group_label": "Patients with chemo-induced anemia"
        }, 
        "brief_summary": {
            "textblock": "This is a non-interventional, descriptive, national, multi-site, longitudinal and\n      prospective observational study with adults patients  who are suffering from cancer or\n      malignant blood disease and whose chemotherapy treatment has induced symptomatic anaemia and\n      being treated with biosimilar of epoetin to correct haemoglobin levels"
        }, 
        "brief_title": "Management of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology", 
        "condition": [
            "Solid Tumors", 
            "Hematological Malignancies", 
            "Chemotherapy-induced Anemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients are 18 years of age or over.\n\n          -  Patients present with chemotherapy-induced symptomatic anaemia.\n\n          -  Patients suffer from solid tumours, malignant lymphomas or multiple myeloma and have\n             developed symptomatic anaemia due to their chemotherapy\n\n          -  Patients can be recruited at any time (from the first to the final chemotherapy\n             cycle.)\n\n          -  Patients would be suited for a course of treatment with epoetin biosimilar\n\n        Exclusion Criteria:\n\n          -  Patients are not undergoing chemotherapy.\n\n          -  Patients have already taken part in a Retacrit\u00ae study.\n\n          -  Patients with contraindications to Retacrit\u00ae\n\n          -  Patients have hypersensitivity to the active principle or to one of the excipients.\n\n          -  Patient with erythroblastopenia, or 'pure red cell aplasia' (PRCA)\n\n          -  Patient with uncontrollable hypertension\n\n          -  An adequate prophylaxis against thrombosis is not practicable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chemotherapy-induced symptomatic anaemia. Patients suffer from solid\n        tumours, malignant lymphomas or multiple myeloma and have developed symptomatic anaemia\n        due to their chemotherapy."
            }
        }, 
        "enrollment": {
            "#text": "2310", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140736", 
            "org_study_id": "1_09.04.2009", 
            "secondary_id": "09.214"
        }, 
        "intervention": {
            "arm_group_label": "Patients with chemo-induced anemia", 
            "intervention_name": "Epoetin biosimilar", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chemotherapy-induced anemia", 
            "Epoetin biosimilar"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sevres", 
                    "country": "France", 
                    "state": "Hauts-de-Seine", 
                    "zip": "92310"
                }, 
                "name": "CLINACT"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Epoetin Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Minist\u00e8re de l'Enseignement sup\u00e9rieur et de la Recherche", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Participants who have hemoglobin values between 11 and 12 g/dl after 6 months of treatment.", 
            "measure": "Change and corrected Hemoglobin levels", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140736"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Observation of blood value development: hemoglobin, hematocrit, reticulocytes, serum iron, ferritin, transferrin saturation", 
            "measure": "Observation of blood value development", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Clinact", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Clinact", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}